ClinicalTrials.gov
public full text
Public Domain
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer#981452
- CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer#1057212
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer#891357
- Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer#826214
- Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer#848242
Record · ID 883207
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive